Insider Selling: SiBone (NASDAQ:SIBN) Insider Sells $72,142.74 in Stock

SiBone (NASDAQ:SIBN) insider Anthony Recupero sold 3,677 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $19.62, for a total value of $72,142.74. Following the transaction, the insider owned 264,467 shares of the company’s stock, valued at $5,188,842.54. This represents a 1.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

SiBone Price Performance

Shares of NASDAQ SIBN opened at $20.88 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 7.97 and a quick ratio of 6.62. The firm has a market capitalization of $906.00 million, a PE ratio of -40.94 and a beta of 0.69. SiBone has a 1-year low of $12.49 and a 1-year high of $21.89. The business’s fifty day moving average price is $18.82 and its two-hundred day moving average price is $17.09.

SiBone (NASDAQ:SIBN) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.05. SiBone had a negative net margin of 11.24% and a negative return on equity of 12.86%. The business had revenue of $48.66 million during the quarter, compared to analyst estimates of $46.67 million. On average, research analysts expect that SiBone will post -0.78 EPS for the current year.

Analysts Set New Price Targets

SIBN has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SiBone in a report on Monday, December 29th. Canaccord Genuity Group raised their target price on SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Truist Financial boosted their price target on SiBone from $21.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Needham & Company LLC raised their price target on SiBone from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Finally, Morgan Stanley upped their price objective on shares of SiBone from $20.00 to $23.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, SiBone has a consensus rating of “Moderate Buy” and an average price target of $25.00.

Hedge Funds Weigh In On SiBone

Hedge funds have recently modified their holdings of the company. State of Alaska Department of Revenue acquired a new stake in shares of SiBone in the third quarter valued at $39,000. State of Wyoming bought a new stake in SiBone in the second quarter worth about $55,000. Canada Pension Plan Investment Board bought a new stake in SiBone in the second quarter worth about $68,000. Quarry LP lifted its holdings in SiBone by 862.6% in the 3rd quarter. Quarry LP now owns 4,861 shares of the company’s stock valued at $72,000 after acquiring an additional 4,356 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in shares of SiBone by 198.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,897 shares of the company’s stock valued at $92,000 after purchasing an additional 3,258 shares in the last quarter. 98.11% of the stock is currently owned by institutional investors and hedge funds.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.